SNSW released its semi-annual performance report, with a net profit attributable to the parent company of 88.96 million yuan, a year-on-year increase of 308.29%

According to the Zhitong Finance APP, SNSW (688117.SH) disclosed its semi-annual report for 2025, reporting revenue of 338 million yuan, a year-on-year increase of 69.69%; net profit attributable to shareholders of the listed company was 88.96 million yuan, a year-on-year increase of 308.29%; net profit excluding non-recurring items was 89.48 million yuan, a year-on-year increase of 367.92%; basic earnings per share were 0.57 yuan.

The net profit attributable to shareholders of the listed company increased by 308.29% compared to the same period last year, mainly due to (1) a significant increase in overseas sales of the raw materials Semaglutide and Teriparatide, leading to increased profits. (2) The delay in the outsourcing project of injectable Octreotide microspheres signed with Meihua Dingchang resulted in unpaid second-phase cooperation funds, leading to a decrease in R&D expenses compared to the same period last year; (3) The price adjustment for the centralized procurement of injectable Octreotide in May 2024 led to a reduction in market business expenses; (4) In March 2025, the return of the land deposit by the Meishan Finance Bureau resulted in a reversal of credit impairment losses of 4 million yuan. The above factors led to an increase in net profit attributable to shareholders of the listed company compared to the same period last year